CVR: 39691175
STIPE Therapeutics ApS was a Danish company of the type Anpartsselskab based in København V, founded in 2018. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company's owners include CLAUS OLESEN HOLDING ApS, Novo Holdings A/S and Sunstone Life Science Ventures Fund IV K/S. The company has 5 employees. In 2024, the company reported a gross profit of DKK -842,285 and a net result of DKK 1,448,748 compared with DKK -4,456,130 the year before. Equity amounted to DKK 1,087,512.
Selskabets formål er udvikling og kommercialisering af lægemidler og hermed forbundet virksomhed.
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationCompared to 1.053 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Contact info changed: new email: [email protected] (February 7, 2026).
On February 7, 2026, STIPE Therapeutics ApS was placed under bankruptcy proceedings.
As of February 3, 2026, EY Godkendt Revisionspartnerselskab has stepped down as auditor of STIPE Therapeutics ApS.
As of February 3, 2026, Preben Jakobsen has stepped down as liquidator of STIPE Therapeutics ApS.
On February 3, 2026, STIPE Therapeutics ApS exited liquidation.
STIPE Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK -842,285, and the net result was DKK 1,448,748.
As of August 21, 2024, Sten Verland has left the board of directors of STIPE Therapeutics ApS.
As of August 21, 2024, Morten Døssing has left the board of directors of STIPE Therapeutics ApS.
As of August 21, 2024, Martin Roelsgaard Jakobsen has left the board of directors of STIPE Therapeutics ApS.
As of August 21, 2024, Regina Hodits has left the board of directors of STIPE Therapeutics ApS.
As of August 21, 2024, Christian Schetter has left the board of directors of STIPE Therapeutics ApS.
As of August 21, 2024, Preben Jakobsen is registered as liquidator of STIPE Therapeutics ApS.
As of August 21, 2024, Claus Elsborg Olesen has stepped down as director of STIPE Therapeutics ApS.
On August 21, 2024, STIPE Therapeutics ApS entered liquidation.
STIPE Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -3,456,557, and the net result was DKK -4,456,130.
As of December 31, 2023, Natalie Rose Sacks has left the board of directors of STIPE Therapeutics ApS.
As of September 14, 2023, Mark David Chin has left the board of directors of STIPE Therapeutics ApS.
As of September 12, 2023, Novo Holdings A/S is registered as an owner of STIPE Therapeutics ApS with an ownership share of 25%.
As of September 8, 2023, Sunstone Life Science Ventures Fund IV K/S is registered as an owner of STIPE Therapeutics ApS with an ownership share of 20%.
As of September 5, 2023, is registered as an owner of STIPE Therapeutics ApS with an ownership share of 20%.
STIPE Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK -6,587,704, and the net result was DKK -8,272,781.
STIPE Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK -4,086,580, and the net result was DKK -5,485,392.
As of December 2, 2021, CLAUS OLESEN HOLDING ApS is registered as an owner of STIPE Therapeutics ApS with an ownership share of 5%.
As of December 2, 2021, MR Jakobsen Holding ApS is registered as an owner of STIPE Therapeutics ApS with an ownership share of 10%.
As of July 31, 2021, Martin Roelsgaard Jakobsen has stepped down as director of STIPE Therapeutics ApS.
As of July 6, 2021, Mark David Chin has joined the board of directors of STIPE Therapeutics ApS.
As of July 6, 2021, John Stephen Cassidy has left the board of directors of STIPE Therapeutics ApS.
STIPE Therapeutics ApS has published its annual report for 2020. Gross profit came to DKK -2,948,722, and the net result was DKK -3,867,652.
As of April 29, 2021, EY Godkendt Revisionspartnerselskab has been appointed auditor of STIPE Therapeutics ApS.
As of February 1, 2021, John Stephen Cassidy has joined the board of directors of STIPE Therapeutics ApS.
As of January 31, 2021, Jonathan Leslie Tobin has left the board of directors of STIPE Therapeutics ApS.
STIPE Therapeutics ApS has published its interim report for the period July 2, 2018 – December 31, 2019.
As of April 6, 2020, Regina Hodits has joined the board of directors of STIPE Therapeutics ApS.
As of April 6, 2020, Natalie Rose Sacks has joined the board of directors of STIPE Therapeutics ApS.
As of October 1, 2019, Sten Verland has joined the board of directors of STIPE Therapeutics ApS.
As of October 1, 2019, Morten Døssing has joined the board of directors of STIPE Therapeutics ApS.
As of October 1, 2019, Martin Roelsgaard Jakobsen has joined the board of directors of STIPE Therapeutics ApS.
As of October 1, 2019, Jonathan Leslie Tobin has joined the board of directors of STIPE Therapeutics ApS.
As of October 1, 2019, Christian Schetter has joined the board of directors of STIPE Therapeutics ApS.
As of July 2, 2018, Claus Elsborg Olesen is registered as director of STIPE Therapeutics ApS.
As of July 2, 2018, Martin Roelsgaard Jakobsen is registered as director of STIPE Therapeutics ApS.
STIPE Therapeutics ApS was founded on July 2, 2018.
Companies in the same industry and area
CVR 45506983
CVR 44695065
CVR 46314964
CVR 40172076
CVR 44828596
companydata.dk